Mode
Text Size
Log in / Sign up

Plasma homocysteine levels associated with increased risk of incident metabolic dysfunction-associated steatotic liver diseaseHigh or low homocysteine levels raise your liver disease risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the positive association between plasma homocysteine levels and incident MASLD in adults.

This observational cohort study enrolled 5,184 adults from the Dalian Health Management Cohort setting. The investigation focused on plasma homocysteine levels as the primary exposure of interest for liver disease outcomes. Participants underwent follow-up for a median duration of 2.66 years to assess incident outcomes of liver disease.

Statistical analysis revealed a positive association between homocysteine levels and incident metabolic dysfunction-associated steatotic liver disease cases. Each standard deviation increase in homocysteine corresponded to an 18% higher risk with a hazard ratio of 1.18. The 95% confidence interval ranged from 1.11 to 1.25. Participants with hyperhomocysteinemia demonstrated a 45% greater risk compared to those without the condition in the baseline analysis. This comparison yielded a hazard ratio of 1.45 with a 95% confidence interval of 1.26 to 1.68. The relationship appeared nonlinear with a U-shaped curve and an inflection point around 10 μmol/L in the observed data set.

Safety data regarding adverse events, serious adverse events, and discontinuations were not reported. The study limitations noted that prior cross-sectional studies often limited by small sample sizes in the literature. Practice relevance was not reported in the provided data. Clinicians should recognize the observational nature of this evidence when considering clinical implications for patient management strategies.

Imagine you are at a doctor's office getting blood work done. You see your homocysteine number on the report. Most people think a high number is bad. But new science suggests the story is more complex than that single number implies.

A large new study looks at how this specific amino acid affects your liver health over time. The findings might change how you view your lab results and your overall metabolic health.

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is a common condition. It involves fat building up in the liver along with other metabolic issues. Doctors now know this condition affects millions of adults worldwide.

Current treatments often focus on diet and exercise. However, many patients still struggle to find effective ways to prevent the disease from starting. Understanding hidden risk factors is crucial for early prevention.

The Twist in the Data

Scientists have studied homocysteine for years. Previous cross-sectional studies often gave conflicting results because they looked at only one moment in time. This new research followed people for years to see what actually happens.

But here is the twist. The relationship between homocysteine and liver disease is not a simple straight line. Instead, it forms a U-shape. This means both extremes of the range can be problematic for your liver.

How The Body Responds

Think of your liver like a busy factory. It needs the right balance of materials to function properly. Homocysteine acts like a chemical signal in your blood. When levels are too high, they can clog the machinery inside your cells.

When levels are too low, the factory might lack essential building blocks. This imbalance can disrupt normal metabolic processes. The body seems to need a specific sweet spot to keep the liver healthy.

Researchers followed 5,184 adults from the Dalian Health Management Cohort. They tracked these participants from 2014 through 2023. The team excluded anyone who already had severe liver disease at the start.

They used liver ultrasounds to check for fat buildup. They also measured metabolic criteria to confirm the diagnosis. The average follow-up time was about two and a half years.

Key Findings

During the study, 1,204 participants developed MASLD. After adjusting for other factors, each standard deviation increase in homocysteine raised the risk by 18%.

People with high homocysteine had a 45% greater risk of developing the disease. This group had levels above 15 micromoles per liter. The risk was significant and independent of other health issues.

This doesn't mean this treatment is available yet.

The analysis showed a clear U-shaped curve. The risk dropped as levels rose from very low points. However, the risk climbed sharply once levels got too high. The turning point was around 10 micromoles per liter.

Experts note that this finding adds to the growing list of metabolic risk factors. It suggests that managing homocysteine could be part of a broader prevention strategy. The field is moving toward personalized medicine where individual biomarkers matter more than general guidelines.

If your lab results show unusual homocysteine levels, talk to your doctor. They can help interpret the number in the context of your full health picture. Do not panic over a single number without professional advice.

Lifestyle changes like eating a balanced diet can help regulate these levels. Your doctor might also check for other causes like vitamin B12 deficiency.

Limitations To Consider

This study had some limitations. It looked at a specific population in Dalian. The results might differ in other groups with different genetics or environments. Also, the study could not prove that changing homocysteine levels will prevent the disease.

More research is needed to confirm these findings in other populations. Scientists are planning larger trials to test interventions that target homocysteine. Until then, maintaining a healthy lifestyle remains the best defense against liver disease.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveMetabolic dysfunction-associated steatotic liver disease (MASLD) is defined by hepatic steatosis accompanied by metabolic abnormalities. Prior cross-sectional studies on the association between plasma homocysteine (Hcy) and MASLD, often limited by small sample sizes, have reported conflicting results.MethodsThis study included 5,184 adults from the Dalian Health Management Cohort (DHMC; 2014–2023), excluding those with baseline MASLD or severe comorbidities. MASLD was diagnosed using liver ultrasonography and metabolic criteria. Hyperhomocysteinemia (HHcy) was defined as a plasma Hcy level >15 μmol/L. Cox proportional hazards models and restricted cubic spline (RCS) analyses evaluated linear and nonlinear associations between baseline Hcy levels and incident MASLD. Subgroup and sensitivity analyses ensured result robustness.ResultsOver a median follow-up of 2.66 years, 1,204 participants developed MASLD. After multivariable adjustment, each standard deviation (SD) increase in Hcy level was associated with a 18% higher risk of incident MASLD (hazard ratio [HR] = 1.18, 95% confidence interval [CI]: 1.11–1.25). Participants with HHcy had a 45% greater risk of developing MASLD compared to those without (HR = 1.45, 95% CI: 1.26–1.68). RCS analysis revealed a U-shaped relationship, with an approximate inflection point around 10 μmol/L identified by restricted cubic spline analysis. Subgroup and sensitivity analyses confirmed these findings.ConclusionPlasma Hcy levels demonstrated a U-shaped, independent association with the risk of incident MASLD, suggesting that both very low and high concentrations may adversely impact hepatic metabolic health.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.